Nykode Therapeutics AS (OSL:NYKD)

Norway flag Norway · Delayed Price · Currency is NOK
1.747
-0.005 (-0.29%)
Aug 22, 2025, 4:27 PM CET
-0.29%
Market Cap570.48M
Revenue (ttm)87.09M
Net Income (ttm)-266.37M
Shares Out326.55M
EPS (ttm)-0.83
PE Ration/a
Forward PEn/a
Dividend1.00 (57.24%)
Ex-Dividend DateMay 27, 2025
Volume354,652
Average Volume446,570
Open1.800
Previous Close1.752
Day's Range1.740 - 1.800
52-Week Range1.550 - 7.190
Beta1.16
RSI47.53
Earnings DateAug 27, 2025

About Nykode Therapeutics AS

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of locally advanced and metastatic tumors; and VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 i... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 136
Stock Exchange Oslo Børs
Ticker Symbol NYKD
Full Company Profile

Financial Performance

In 2024, Nykode Therapeutics AS's revenue was $9.16 million, a decrease of -31.26% compared to the previous year's $13.32 million. Losses were -$38.82 million, 10.4% more than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.